| 臺大學術典藏 |
2021-09-15T01:20:47Z |
The expression levels of long non-coding RNA KIAA0125 are associated with distinct clinical and biological features in myelodysplastic syndromes
|
Hung S.-Y.; Lin C.-C.; CHIA-LANG HSU; Yao C.-Y.; Wang Y.-H.; Tsai C.-H.; Hou H.-A.; Chou W.-C.; Tien H.-F. |
| 臺大學術典藏 |
2021-09-15T01:20:47Z |
Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125
|
Wang Y.-H.; Lin C.-C.; CHIA-LANG HSU; Hung S.-Y.; Yao C.-Y.; Lee S.-H.; Tsai C.-H.; Hou H.-A.; Chou W.-C.; Tien H.-F. |
| 臺大學術典藏 |
2021-09-09T05:25:29Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
ZONG-HAN YAO; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-09T05:25:27Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients
|
ZONG-HAN YAO; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-04T06:11:42Z |
Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-na?ve Taiwanese patients with chronic hepatitis B
|
Chien R.-N.; Peng C.-Y.; JIA-HORNG KAO; Hu T.-H.; Lin C.-C.; Hu C.-T.; Chen C.-Y.; Hsieh T.-Y.; Lin H.-C.; Chuang W.-L. |
| 臺大學術典藏 |
2021-09-04T06:11:08Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; JIA-HORNG KAO; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 臺大學術典藏 |
2021-09-04T03:10:20Z |
Subconjunctival herniated orbital fat mimicking adipocytic neoplasm
|
Lin C.C.; SHU-LANG LIAO; Liou S.W.; Chen C.C.; Wu Y.Y.; Woung L.C. |
| 臺大學術典藏 |
2021-09-04T03:10:15Z |
Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves’ Orbitopathy
|
Shih S.-R.; SHU-LANG LIAO; Shih C.-W.; Wei Y.-H.; Lu T.-X.; Chou C.-H.; Yen E.-Y.; Chang Y.-C.; Lin C.-C.; Chi Y.-C.; Yang W.-S.; Tsai F.-C. |
| 臺大學術典藏 |
2021-09-02T00:08:48Z |
Toward Fast Platform-Aware Neural Architecture Search for FPGA-Accelerated Edge AI Applications
|
Liang Y.-C;Liao Y.-C;Lin C.-C;Hung S.-H.; Liang Y.-C; Liao Y.-C; Lin C.-C; Hung S.-H.; SHIH-HAO HUNG |
| 臺大學術典藏 |
2021-09-02T00:04:44Z |
Simulation model of multiple oxide-aperture VCSEL
|
Hsu S.-C;Huang Y.-M;Cho Y.-Y;Peng C.-Y;Wu C.-H;Lin G.-R;Kuo H.-C;Lin C.-C.; Hsu S.-C; Huang Y.-M; Cho Y.-Y; Peng C.-Y; Wu C.-H; Lin G.-R; Kuo H.-C; Lin C.-C.; GONG-RU LIN |
| 臺大學術典藏 |
2021-09-02T00:04:43Z |
Simulation Model of Multiple Oxide-Aperture VCSEL
|
Hsu S.-C;Huang Y.-M;Cjo Y.-Y;Peng C.-Y;Wu C.-H;Lin G.-R;Kuo H.-C;Lin C.-C.; Hsu S.-C; Huang Y.-M; Cjo Y.-Y; Peng C.-Y; Wu C.-H; Lin G.-R; Kuo H.-C; Lin C.-C.; GONG-RU LIN |
| 臺大學術典藏 |
2021-09-02T00:04:20Z |
The photonic properties of micro/mini LED arrays with different substrate thickness
|
Yang S.-M;Wang P.-H;Chao C.-H;Chu C.-W;Chen Y.-S;Chang F.-P;Fang Y.-H;Lin C.-C;Wu C.-I.; Yang S.-M; Wang P.-H; Chao C.-H; Chu C.-W; Chen Y.-S; Chang F.-P; Fang Y.-H; Lin C.-C; Wu C.-I.; CHIH-I WU |
| 臺大學術典藏 |
2021-09-02T00:04:19Z |
High-end displays applications by micro-leds
|
Lin C.-C;Fang Y.-H;Kuo W.-H;Liang K.-L;Tseng J.T;Hu P.H;Lin M.C;Wu C.-I.; Lin C.-C; Fang Y.-H; Kuo W.-H; Liang K.-L; Tseng J.T; Hu P.H; Lin M.C; Wu C.-I.; CHIH-I WU |
| 臺大學術典藏 |
2021-09-02T00:04:18Z |
High Speed Mach Zehnder Modulator with Low Series Resistance Phase Shifter Loaded in Traveling Wave Electrode
|
Ku K.-N;Chang P.-C;Wang C.-C;Lin C.-Y;Hsu C.-H;Chen T.-H;Huang C.-Y;Lee C.-S;Chen Y.-F;Chou K.-W;Chen S.-C;Lee M.-C;Lin C.-C;Chu M.-T;Wu C.-I.; Ku K.-N; CHIH-I WU et al. |
| 臺大學術典藏 |
2021-09-02T00:04:17Z |
Extended Electrical and Photonic Characterization of GaN-Based Ultra-Violet MicroLEDs with an ITO Emission Window Layer
|
Tsai Y.-L;Huang S.-K;Huang H.-H;Yang S.-M;Liang K.-L;Kuo W.-H;Fang Y.-H;Wu C.-I;Wang S.-W;Shih H.-Y;Xu Z;Cho M;Shen S.-C;Lin C.-C.; Tsai Y.-L; CHIH-I WU et al. |
| 臺大學術典藏 |
2021-09-02T00:04:15Z |
Analysis of Racetrack-Coupled Mach Zehnder Interferometer for High-Speed Communication
|
Ku K.-N;Chang P.-C;Wang C.-C;Lin C.-Y;Hsu C.-H;Chen T.-H;Huang C.-Y;Wun S.-J;Lee C.-S;Chen S.-C;Lee M.-C;Lin C.-C;Wu C.-I.; Ku K.-N; CHIH-I WU et al. |
| 臺大學術典藏 |
2021-09-02T00:04:14Z |
A Frequency Digital Pre-Distortion Compensation Method for FMCW LiDAR System
|
Chen T.-H;Huang C.-Y;Shia T.K;Wun S.-J;Hsu C.-H;Ku K.-N;Lee C.-S;Lin C.-Y;Chang P.-C;Wang C.-C;Chen S.-C;Lin C.-C;Wu C.I.; Chen T.-H; CHIH-I WU et al. |
| 臺大學術典藏 |
2021-09-02T00:04:14Z |
A frequency digital pre-distortion compensation method for FMCW LiDAR system
|
Chen T.-H;Huang C.-Y;Shia T.K;Wun S.-J;Hsu C.-H;Ku K.-N;Lee C.-S;Lin C.-Y;Chang P.-C;Wang C.-C;Chen S.-C;Lin C.-C;Wu C.-I.; Chen T.-H; CHIH-I WU et al. |
| 臺大學術典藏 |
2021-09-02T00:03:46Z |
Near-CAZAC Preamble Sequences for Initial Synchronization in Spectrally Compact OFDM
|
Lin C.-C;Chen W.-C;Chung C.-D.; Lin C.-C; Chen W.-C; Chung C.-D.; CHAR-DIR CHUNG |
| 臺大學術典藏 |
2021-09-02T00:03:43Z |
Simulation Model of Multiple Oxide-Aperture VCSEL
|
Hsu S.-C;Huang Y.-M;Cjo Y.-Y;Peng C.-Y;Wu C.-H;Lin G.-R;Kuo H.-C;Lin C.-C.; Hsu S.-C; Huang Y.-M; Cjo Y.-Y; Peng C.-Y; Wu C.-H; Lin G.-R; Kuo H.-C; Lin C.-C.; CHAO-HSIN WU |
| 臺大學術典藏 |
2021-09-02T00:03:43Z |
Simulation model of multiple oxide-aperture VCSEL
|
Hsu S.-C;Huang Y.-M;Cho Y.-Y;Peng C.-Y;Wu C.-H;Lin G.-R;Kuo H.-C;Lin C.-C.; Hsu S.-C; Huang Y.-M; Cho Y.-Y; Peng C.-Y; Wu C.-H; Lin G.-R; Kuo H.-C; Lin C.-C.; CHAO-HSIN WU |
| 臺大學術典藏 |
2021-09-01T02:02:30Z |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer
|
Lin C.-C.; Hsu C.-H.; Chen J.; Tsai T.-C.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:26Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H.; ANN-LII CHENG; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; Yeh K.-H. |
| 臺大學術典藏 |
2021-09-01T02:02:11Z |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; ANN-LII CHENG; Chen J.; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:09Z |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; Wang H.-P.; Lee J.-M.; Yeh K.-H.; Yang C.-H.; Lin J.-T.; ANN-LII CHENG; Lee Y.-C. |
| 臺大學術典藏 |
2021-09-01T02:02:09Z |
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; ANN-LII CHENG; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:08Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C.; ANN-LII CHENG; Hsu C.-H.; Lu Y.-S.; Hsu C.; Yeh K.-H.; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T02:02:07Z |
Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial
|
Lin C.-C.; Hsu C.; Hsu C.-H.; Hsu W.-L.; ANN-LII CHENG; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T02:02:06Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:33Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:32Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C.; Yeh K.-H.; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:32Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Lin C.-C.; Hsu C.-H.; Hour T.-C.; ANN-LII CHENG; Huang C.-Y.; Huang K.-H.; Chen J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:29Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; ANN-LII CHENG; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:27Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Lin C.-C.; Pu Y.-S.; Hsu C.-H.; Keng H.-Y.; ANN-LII CHENG; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:26Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; ANN-LII CHENG; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:24Z |
National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital
|
Lin C.-C.; Yang C.-H.; ANN-LII CHENG; Chan W.-K.; Ho N.-N. |
| 臺大學術典藏 |
2021-09-01T01:54:19Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; Huang C.-Y.; Tsai Y.-C.; Hsu F.-M.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:53:45Z |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy
|
Chen W.-W.; Lin C.-C.; Huang T.-C.; ANN-LII CHENG; Yeh K.-H.; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:42:27Z |
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
|
Ghamande S.; Lin C.-C.; Cho D.C.; Shapiro G.I.; Kwak E.L.; Silverman M.H.; Tseng Y.; Kuo M.-W.; Mach W.B.; Hsu S.-C.; Coleman T.; Yang J.C.-H.; ANN-LII CHENG; Ghalib M.H.; Chuadhary I.; Goel S. |
| 臺大學術典藏 |
2021-08-31T06:42:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; Yeh K.-H.; Lu Y.-S.; ANN-LII CHENG; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:48Z |
Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma
|
Guo J.-C.; Huang T.-C.; Lin C.-C.; Hsieh M.-S.; Chang C.-H.; Huang P.-M.; Lee J.-M.; Hsu F.-M.; Cheng J.C.-H.; Wang H.-P.; Yeh K.-H.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y.; Cheng J.C.-H.; Huang C.-Y.; Tsai Y.-C.; Lin C.-C.; Hsu C.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2021-08-31T06:29:26Z |
A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma
|
Yang S.-H.; Shao Y.-Y.; Lin C.-C.; Kuo S.-H.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:25Z |
Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
|
Doi T.; Yang J.C.-H.; Shitara K.; Naito Y.; ANN-LII CHENG; Sarashina A.; Pronk L.C.; Takeuchi Y.; Lin C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:24Z |
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
|
Huang T.-C.; Lin C.-C.; Wu Y.-C.; Chia-Hsien Cheng J.; Lee J.-M.; Wang H.-P.; Huang P.-M.; Hsu F.-M.; Yeh K.-H.; ANN-LII CHENG; Tzen K.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; ANN-LII CHENG; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T03:33:46Z |
151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs
|
Liao B.-C.; Bai Y.-Y.; Lin C.-C.; SHU-YUNG LIN; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Yang J. |
| 臺大學術典藏 |
2021-08-31T03:33:45Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
SHU-YUNG LIN; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
